Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Mirati Therapeutics, Inc. - Common Stock (NQ: MRTX )

N/A UNCHANGED
Last Price Updated: 4:00 PM EST, Jan 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open -
Bid (Size) 58.85 (1)
Ask (Size) 59.74 (10)
Prev. Close 58.70
Today's Range N/A - N/A
52wk Range 58.60 - 59.46
Shares Outstanding 51,623,193
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Upward Trajectory For Biotech/Pharma M&A: Sector Trends Towards Pre-Pandemic Levels, Forecasts Positive For 2024
According to the Global Data report, the pharma sector in Q3 2023 witnessed deals worth $28 billion, down 28% from the $54 billion recorded in Q2 2023.  
Via Benzinga
EnerSys To Rally Around 20%? Here Are 10 Top Analyst Forecasts For Wednesday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. 
Via Benzinga

Performance

More News

Read More
Analyst Expectations For Mirati Therapeutics's Future
Via Benzinga
Improving Survival Rates: Biotech Innovations in Pancreatic Cancer Treatment
Via FinancialNewsMedia
Topics Death
Exposures Death
What 11 Analyst Ratings Have To Say About Mirati Therapeutics
Via Benzinga
3 Resilient Stocks with Massive Potential to Boost Your Wealth
Via InvestorPlace
These Three Biotech Stocks Are Trading At A Discount
Via Talk Markets
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
3 Biotech Stocks That Could Boom or Bust by 2025
Via InvestorPlace
MIRATI THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Mirati Therapeutics, Inc. - MRTX
From Kahn Swick & Foti, LLC
Via Business Wire
3 No-Brainer Stocks to Buy With $500 Right Now
Via The Motley Fool
Appian To Rally Around 47%? Here Are 10 Top Analyst Forecasts For Tuesday
Via Benzinga
Is MIRATI THERAPEUTICS INC Ready to Break Out of Its Range?
Via Chartmill
7 Healthcare Stocks That Can Cure a Lackluster Portfolio
Via InvestorPlace
Opdivo's Subcutaneous Formulation Shows Promise in Advanced Kidney Cancer: Bristol Myers Squibb's Latest Findings
Via Benzinga
Bristol Myers Squibb Enters the Multi-Billion-Dollar Oncology Race
Via PressReach
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Consolidated Communications Holdings, Inc. (Nasdaq – CNSL), Mirati Therapeutics, Inc.® (Nasdaq - MRTX), Pioneer Natural Resources (NYSE - PXD), Summit Materials (NYSE
From Brodsky & Smith LLC
Via GlobeNewswire
Amgen Stock Surges To 10-Month High, Up 4% On An Unexpected Upgrade
Via Investor's Business Daily
Benzinga's Top Ratings Upgrades, Downgrades For October 10, 2023
Via Benzinga
Elli Lilly Joins Big Pharma’s Multi-Billion-Dollar Oncology Race
Via PressReach
MIRATI THERAPEUTICS INVESTOR ALERT By the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Mirati Therapeutics, Inc. - MRTX
From Kahn Swick & Foti, LLC
Via Business Wire
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Why Shares of Tango Therapeutics Are Dropping Monday
Via The Motley Fool
Benzinga's Top Ratings Upgrades, Downgrades For October 9, 2023
Via Benzinga
Why ParaZero Technologies Shares Are Trading Higher By Over 100%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Via Benzinga
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.